{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:17:14Z","timestamp":1766049434136,"version":"3.44.0"},"reference-count":180,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128164228"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/b978-0-12-816422-8.00018-0","type":"book-chapter","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T05:48:00Z","timestamp":1598593680000},"page":"415-457","source":"Crossref","is-referenced-by-count":4,"title":["Present and future perspectives for targeting histone modifications in therapy"],"prefix":"10.1016","author":[{"given":"V\u00e2nia","family":"Camilo","sequence":"first","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev.biochem.76.052705.162114","article-title":"Functions of site-specific histone acetylation and deacetylation","volume":"76","author":"Shahbazian","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/jsbi.2000.4217","article-title":"Review: chromatin structural features and targets that regulate transcription","volume":"129","author":"Wolffe","year":"2000","journal-title":"J Struct Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0025","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors","volume":"102","author":"Peart","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0030","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.7150\/jca.23427","article-title":"Histone methylation in DNA repair and clinical practice: new findings during the past 5-years","volume":"9","author":"Wei","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature04815","article-title":"A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling","volume":"442","author":"Wysocka","year":"2006","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/35065138","article-title":"Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain","volume":"410","author":"Bannister","year":"2001","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002376","article-title":"Histone H3K56 acetylation, CAF1, and Rtt106 coordinate nucleosome assembly and stability of advancing replication forks","volume":"7","author":"Clemente-Ruiz","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0050","doi-asserted-by":"crossref","first-page":"28553","DOI":"10.1074\/jbc.M110.149393","article-title":"p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals","volume":"285","author":"Vempati","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0055","doi-asserted-by":"crossref","first-page":"11414","DOI":"10.18632\/oncotarget.23356","article-title":"Role of novel histone modifications in cancer","volume":"9","author":"Shanmugam","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0065","doi-asserted-by":"crossref","first-page":"2608605","DOI":"10.1155\/2017\/2608605","article-title":"The histone modification code in the pathogenesis of autoimmune diseases","volume":"2017","author":"Araki","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","article-title":"Lessons from the cancer genome","volume":"153","author":"Garraway","year":"2013","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-016-0279-9","article-title":"Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives","volume":"9","author":"Song","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0090","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/leu.2013.204","article-title":"Point mutation E1099K in MMSET\/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies","volume":"28","author":"Oyer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0095","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0100","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/cancers11030324","article-title":"Expanding the role of the histone lysine-specific demethylase LSD1 in cancer","volume":"11","author":"Majello","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0105","doi-asserted-by":"crossref","DOI":"10.1101\/gad.2057811","article-title":"The diverse functions of Dot1 and H3K79 methylation","author":"Nguyen","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2141.2001.03000.x","article-title":"Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992","volume":"114","author":"Andersen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0115","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0130","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/B978-0-12-816422-8.00018-0_bb0135","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","article-title":"Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia","volume":"128","author":"Shukla","year":"2016","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0145","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/leu.2010.311","article-title":"EZH2 Y641 mutations in follicular lymphoma","volume":"25","author":"B\u00f6d\u00f6r","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0150","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ni876","article-title":"Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement","volume":"4","author":"Su","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0165","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"Lafave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","article-title":"UTX\/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition","volume":"21","author":"Ezponda","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0175","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0180","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0185","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0190","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0195","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0200","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1634\/theoncologist.2017-0644","article-title":"Panobinostat and multiple myeloma in 2018","volume":"23","author":"Yee","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0205","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2017-0301","article-title":"EMA review of panobinostat (Farydak) for the treatment of adult patients with relapsed and\/or refractory multiple myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0215","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"Karkhanis","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0220","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0225","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ijc.25366","article-title":"Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers","volume":"128","author":"Yoshimatsu","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor activity of the Type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-9525(03)00115-X","article-title":"The diverse functions of histone acetyltransferase complexes","volume":"19","author":"Carrozza","year":"2003","journal-title":"Trends Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0240","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/sj.onc.1210602","article-title":"Hat1: the emerging cellular roles of a type B histone acetyltransferase","volume":"26","author":"Parthun","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0245","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.sbi.2008.11.004","article-title":"Catalysis and substrate selection by histone\/protein lysine acetyltransferases","volume":"18","author":"Berndsen","year":"2008","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0250","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1101\/gad.236331.113","article-title":"Histone target selection within chromatin: an exemplary case of teamwork","volume":"28","author":"Lalonde","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0255","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/sj.onc.1210604","article-title":"Distinct GCN5\/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation","volume":"26","author":"Nagy","year":"2007","journal-title":"Oncogene"},{"issue":"6595","key":"10.1016\/B978-0-12-816422-8.00018-0_bb0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/383099a0","article-title":"Role of CBP\/P300 in nuclear receptor signalling","volume":"383","author":"Chakravarti","year":"1996","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0265","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1038\/sj.onc.1210608","article-title":"The MYST family of histone acetyltransferases and their intimate links to cancer","volume":"26","author":"Avvakumov","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-016-0225-2","article-title":"Histone acetyltransferases: challenges in targeting bi-substrate enzymes","volume":"8","author":"Wapenaar","year":"2016","journal-title":"Clin Epigenetics"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0275","series-title":"Epigenetic Cancer Therapy","first-page":"31","article-title":"Writers, readers, and erasers of epigenetic marks","author":"Nicholson","year":"2015"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0280","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41594-019-0290-2","article-title":"Targeting non-bromodomain chromatin readers","volume":"26","author":"Arrowsmith","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0285","first-page":"659","article-title":"The role of human bromodomains in chromatin biology and gene transcription","volume":"12","author":"Sanchez","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0290","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0295","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0300","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0305","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2018-0115","article-title":"Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy","volume":"5","author":"Alqahtani","year":"2019","journal-title":"Future Sci OA"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0310","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.biochem.78.070907.103946","article-title":"Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases","volume":"79","author":"Mosammaparast","year":"2010","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0315","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bbagrm.2013.05.002","article-title":"The histone LSD1 demethylase in stemness and cancer transcription programs","volume":"1829","author":"Amente","year":"2013","journal-title":"Biochim Biophys Acta, Gene Regul Mech"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0320","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","article-title":"The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells","volume":"21","author":"Harris","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0325","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nm.2661","article-title":"Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia","volume":"18","author":"Schenk","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0330","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/molecules23123194","article-title":"Pharmacological inhibition of LSD1 for cancer treatment","volume":"23","author":"Yang","year":"2018","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/B978-0-12-816422-8.00018-0_bb0335","doi-asserted-by":"crossref","first-page":"a026484","DOI":"10.1101\/cshperspect.a026484","article-title":"Histone lysine demethylase inhibitors","author":"Jambhekar","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5507\/bp.2013.085","article-title":"Histone deacetylase inhibitors in cancer therapy. A review","volume":"158","author":"Hrabeta","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0345","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0350","doi-asserted-by":"crossref","DOI":"10.1186\/1868-7083-4-5","article-title":"Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors","volume":"4","author":"Delcuve","year":"2012","journal-title":"Clin Epigenetics"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0355","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00018-012-0921-9","article-title":"Multiple roles of class I HDACs in proliferation, differentiation, and development","volume":"69","author":"Reichert","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0360","first-page":"129383","article-title":"Physiological roles of class I HDAC complex and histone demethylase","volume":"2011","author":"Nakayama","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0365","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1582-4934.2011.01321.x","article-title":"Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis","volume":"15","author":"Clocchiatti","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0370","doi-asserted-by":"crossref","first-page":"14329","DOI":"10.1073\/pnas.250494697","article-title":"Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras","volume":"97","author":"Zhou","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0375","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0380","doi-asserted-by":"crossref","first-page":"17335","DOI":"10.1073\/pnas.0706487104","article-title":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases","volume":"104","author":"Lahm","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0385","doi-asserted-by":"crossref","first-page":"10572","DOI":"10.1073\/pnas.191375098","article-title":"Cloning and characterization of a histone deacetylase, HDAC9","volume":"98","author":"Zhou","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0390","doi-asserted-by":"crossref","first-page":"35826","DOI":"10.1074\/jbc.M104935200","article-title":"Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo","volume":"276","author":"Fischle","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(01)00429-4","article-title":"Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT\/N-CoR","volume":"9","author":"Fischle","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0400","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/MCB.25.8.2873-2884.2005","article-title":"Class II histone deacetylases: from sequence to function, regulation, and clinical implication","volume":"25","author":"Yang","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0405","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0168-9525(03)00073-8","article-title":"Class II histone deacetylases: versatile regulators","volume":"19","author":"Verdin","year":"2003","journal-title":"Trends Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0410","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbagrm.2017.12.002","article-title":"HDAC11 is a regulator of diverse immune functions","volume":"1861","author":"Yanginlar","year":"2018","journal-title":"Biochim Biophys Acta, Gene Regul Mech"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0415","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0420","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","article-title":"HDAC6 modulates cell motility by altering the acetylation level of cortactin","volume":"27","author":"Zhang","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0425","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0430","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1101\/gad.436407","article-title":"HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates","volume":"21","author":"Boyault","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0435","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nature05853","article-title":"HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS","volume":"447","author":"Pandey","year":"2007","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0440","first-page":"971","article-title":"Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B","volume":"2","author":"Fuino","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0445","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-06-3093","article-title":"Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-\u03b1 levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90","volume":"13","author":"Fiskus","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0450","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1091\/mbc.e05-01-0033","article-title":"Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins","volume":"16","author":"Michishita","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0455","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/acel.12685","article-title":"Sirtuins at the crossroads of stemness, aging, and cancer","volume":"16","author":"O\u2019Callaghan","year":"2017","journal-title":"Aging Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0460","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/ars.2017.7290","article-title":"The role of sirtuins in antioxidant and redox signaling","volume":"28","author":"Singh","year":"2018","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0465","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cytogfr.2017.11.001","article-title":"Nuclear sirtuins and inflammatory signaling pathways","volume":"38","author":"Mendes","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0470","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/apt.13008","article-title":"Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases","volume":"41","author":"Felice","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0475","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1358\/dnp.2009.22.9.1437959","article-title":"Histone deacetylases as targets for the treatment of human neurodegenerative diseases","volume":"22","author":"D\u2019Mello","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0480","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ng1773","article-title":"A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition","volume":"38","author":"Ropero","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0485","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.07.078","article-title":"An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1","volume":"135","author":"Hanigan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0490","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/s002800100302","article-title":"Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins","volume":"48","author":"Hiebert","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0495","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1038\/sj.onc.1204853","article-title":"Transcriptional regulation in acute promyelocytic leukemia","volume":"20","author":"Lin","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0500","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI200111537","article-title":"Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia","volume":"108","author":"He","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0505","first-page":"2","article-title":"Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia","volume":"61","author":"Ferrara","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0510","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1365-2141.2000.01933.x","article-title":"Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid","volume":"108","author":"Kitamura","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0515","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0520","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1073\/pnas.0408732102","article-title":"Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors","volume":"102","author":"Ungerstedt","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0525","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1091\/mbc.11.6.2069","article-title":"Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells","volume":"11","author":"Qiu","year":"2000","journal-title":"Mol Biol Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0530","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1074\/jbc.M106699200","article-title":"Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas\/Fas ligand expression in human acute promyelocytic leukemia cells","volume":"277","author":"Kwon","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb9000","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.191208598","article-title":"The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species","volume":"98","author":"Ruefli","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0535","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/bjc.2013.742","article-title":"P53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors","volume":"110","author":"Sonnemann","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0540","doi-asserted-by":"crossref","first-page":"522","DOI":"10.21037\/atm.2016.12.40","article-title":"P53 mutations and cancer: a tight linkage","volume":"4","author":"Perri","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0545","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0550","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/exd.13159","article-title":"Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism","volume":"26","author":"Hrgovic","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0555","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes","volume":"7","author":"Kim","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0560","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3390\/ijms20092241","article-title":"Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy","volume":"20","author":"Banik","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0565","first-page":"151","article-title":"Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines","volume":"2","author":"Glaser","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0570","first-page":"67","article-title":"DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines","volume":"2","author":"Labonte","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0575","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0580","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0585","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41598-017-03417-1","article-title":"Novel class IIa-selective histone deacetylase inhibitors discovered using an in silico virtual screening approach","volume":"7","author":"Hsu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0590","first-page":"35","article-title":"Clinical use and applications of histone deacetylase inhibitors in multiple myeloma","volume":"8","author":"Tandon","year":"2016","journal-title":"Clin Pharm"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0595","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0600","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0605","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.13315","article-title":"Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death","volume":"169","author":"Mishima","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0610","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0615","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"Holien","year":"2012","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0620","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0625","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0630","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.38","article-title":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","volume":"5","author":"Hideshima","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0635","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0640","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0645","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.2018.36.15_suppl.1058","article-title":"Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer","volume":"36","author":"Kalinsky","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0650","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.gore.2019.07.010","article-title":"Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer","volume":"29","author":"Lee","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0655","first-page":"539","article-title":"Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status","volume":"24","author":"Chobanian","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0660","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/j.pain.0000000000000893","article-title":"HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy","volume":"158","author":"Krukowski","year":"2017","journal-title":"Pain"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0665","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/toxics3020152","article-title":"Taxane-induced peripheral neurotoxicity","volume":"3","author":"Velasco","year":"2015","journal-title":"Toxics"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0670","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.18632\/oncotarget.13738","article-title":"Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor","volume":"12","author":"North","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0680","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0685","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.24260","article-title":"Epigenetic therapy for Friedreich ataxia","volume":"76","author":"Soragni","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0690","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40673-017-0062-x","article-title":"Friedreich Ataxia: current status and future prospects","volume":"4","author":"B\u00fcrk","year":"2017","journal-title":"Cerebellum Ataxias"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0695","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study","volume":"384","author":"Libri","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0700","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0705","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","article-title":"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0710","doi-asserted-by":"crossref","first-page":"10542","DOI":"10.1200\/JCO.2018.36.15_suppl.10542","article-title":"Phase I multicenter trial of CUDC-907 in children and young adults with relapsed\/refractory solid tumors, CNS tumors, and lymphomas","volume":"36","author":"Shulman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0715","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/cas.12002","article-title":"Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase\/phosphatidylinositol 3-kinase dual inhibitors","volume":"103","author":"Saijo","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0720","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","article-title":"CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity","volume":"70","author":"Lai","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0725","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer","volume":"53","author":"Cai","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0730","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-14-0570","article-title":"Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors","volume":"20","author":"Shimizu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0735","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/1078-0432.CCR-14-2820","article-title":"A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma","volume":"21","author":"Galloway","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0740","doi-asserted-by":"crossref","first-page":"16650","DOI":"10.18632\/oncotarget.7692","article-title":"The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias","volume":"7","author":"Zabkiewicz","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0745","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bjh.12359","article-title":"A phase I first-in-human study with tefinostat\u2014a monocyte\/macrophage targeted histone deacetylase inhibitor\u2014in patients with advanced haematological malignancies","volume":"162","author":"Ossenkoppele","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0750","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2018-99-110356","article-title":"Results of a phase 2 trial of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukemia (CMML)\u2014the UK monocle study","volume":"132","author":"Knapper","year":"2018","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0755","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1016\/j.bmcl.2013.03.108","article-title":"Dual-acting histone deacetylase-topoisomerase I inhibitors","volume":"23","author":"Guerrant","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0760","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/jm200799p","article-title":"Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors","volume":"55","author":"Guerrant","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0765","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/mol.116.103416","article-title":"Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease heat shock protein 90 and androgen receptor levels and inhibit viability in enzalutamide-resistant C4-2 prostate cancer cells","volume":"90","author":"Rosati","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0770","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1021\/jm400467w","article-title":"Histone deacetylase inhibitors equipped with estrogen receptor modulation activity","volume":"56","author":"Gryder","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0775","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1016\/j.bmcl.2013.04.067","article-title":"Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0780","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.bmc.2010.03.078","article-title":"Vitamin D receptor agonist\/histone deacetylase inhibitor molecular hybrids","volume":"18","author":"Lamblin","year":"2010","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0785","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmech.2017.04.017","article-title":"Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors","volume":"134","author":"Yuan","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0790","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cbpa.2019.03.002","article-title":"Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer","volume":"50","author":"Stazi","year":"2019","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0795","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0800","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0805","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.it.2011.04.001","article-title":"Histone deacetylases as regulators of inflammation and immunity","volume":"32","author":"Shakespear","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0810","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/icb.2011.88","article-title":"HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation","volume":"90","author":"Sweet","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0815","doi-asserted-by":"crossref","first-page":"25362","DOI":"10.1074\/jbc.M113.496281","article-title":"Histone deacetylase 7 promotes toll-like receptor 4-dependent proinflammatory gene expression in macrophages","volume":"288","author":"Shakespear","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0820","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1101\/gad.552310","article-title":"Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression","volume":"24","author":"Yamaguchi","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0825","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ni.2008","article-title":"Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes","volume":"12","author":"Navarro","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0830","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/BJ20061085","article-title":"Recruitment of histone deacetylase 4 by transcription factors represses interleukin-5 transcription","volume":"400","author":"Han","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0835","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002873","article-title":"Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms","volume":"5","author":"Beier","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0840","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1074-7613(04)00078-0","article-title":"HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization","volume":"20","author":"Serrador","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0845","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1091\/mbc.e06-01-0008","article-title":"Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity","volume":"17","author":"Cabrero","year":"2006","journal-title":"Mol Biol Cell"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0850","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ni.1673","article-title":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance","volume":"10","author":"Villagra","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0855","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molimm.2014.08.002","article-title":"Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function","volume":"63","author":"Sahakian","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0860","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1189\/jlb.1A0415-176RRR","article-title":"Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology","volume":"102","author":"Sahakian","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0865","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood-2016-08-731505","article-title":"T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model","volume":"130","author":"Woods","year":"2017","journal-title":"Blood"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0870","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.1302778","article-title":"A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3\/IL-10 pathway in APCs","volume":"193","author":"Cheng","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0875","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molimm.2014.02.019","article-title":"Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells","volume":"60","author":"Cheng","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0880","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0885","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0890","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejmech.2015.04.014","article-title":"Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids","volume":"96","author":"Sodji","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0895","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1158\/0008-5472.CAN-04-2550","article-title":"Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells","volume":"64","author":"Farokhzad","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-816422-8.00018-0_bb0900","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"}],"container-title":["Histone Modifications in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128164228000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128164228000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:42:50Z","timestamp":1757677370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128164228000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128164228"],"references-count":180,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-816422-8.00018-0","relation":{},"subject":[],"published":{"date-parts":[[2020]]}}}